ストックスクリーナーアプリを入手
112.46
8.66%
8.96
Biontech Se Adr (BNTX) 最新ニュース
Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday - Benzinga
Pfizer and BioNTech: Slightly Lowering Our MRNA Vaccine Forecast Due to US Policy Headwinds - Morningstar
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 - GlobeNewswire Inc.
BioNTech SE Sponsored ADR $BNTX Shares Acquired by HighTower Advisors LLC - Defense World
Cresset Asset Management LLC Sells 1,035 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
BioNTech’s Promising Phase III Study in Recurrent Endometrial Cancer - The Globe and Mail
BioNTech SE Sponsored ADR $BNTX Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
BioNTech’s Promising NSCLC Study: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
BioNTech’s Promising Phase III Study on Recurrent Endometrial Cancer - The Globe and Mail
BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN
Pfizer and BioNTech’s Combined Vaccine Study: A Potential Game-Changer - TipRanks
BioNTech ADR Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
HC Wainwright Has Bearish Estimate for BioNTech Q3 Earnings - Defense World
BioNTech’s Phase II Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment - MSN
US Bancorp DE Cuts Stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s New Study on Breast Cancer Treatment: A Potential Game-Changer? - The Globe and Mail
BioNTech (NASDAQ:BNTX) Price Target Lowered to $136.00 at HC Wainwright - Defense World
BioNTech’s BNT113 Trial: A Potential Game-Changer in Head and Neck Cancer Treatment - TipRanks
BioNTech’s Latest Clinical Study: A New Hope for Advanced Breast Cancer Treatment - The Globe and Mail
BioNTech’s BNT327 Trial: A New Hope for Small-cell Lung Cancer? - TipRanks
BioNTech’s Promising Trial: BNT113 and Pembrolizumab in Head and Neck Cancer - The Globe and Mail
BioNTech’s Promising Lung Cancer Study: A Potential Game-Changer in Oncology - TipRanks
BioNTech’s BNT327 Study: A New Hope for Lung Cancer Treatment? - The Globe and Mail
BioNTech’s Promising Phase II Study on BNT327 for Small-cell Lung Cancer - The Globe and Mail
Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail
BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks
BioNTech SE’s BNT331 Safety Trial: A Potential Game-Changer in Women’s Health - TipRanks
Genmab and BioNTech’s Promising Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech ADR Earns RS Rating Upgrade - Investor's Business Daily
BioNTech’s Strategic Moves and Financial Outlook - The Globe and Mail
BioNTech SE Earnings Call: Strategic Growth Amid Challenges - TipRanks
Genmab and BioNTech SE’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech Earnings: Guidance Reiterated; Incremental Progress in Clinical Trials - Morningstar
BioNTech ADR Earns Relative Strength Rating Upgrade - MSN
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update04.08.25News - Ariva
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
BioNTech's mRNA Revolution: Unlocking Long-Term Value in Personalized Oncology and Global Vaccines - AInvest
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - The Globe and Mail
BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday - Defense World
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know - Yahoo Finance
Cancer Vaccine Market Research Service Featuring the Top 5 Developers and Pipeline Activities - GlobeNewswire Inc.
Best Momentum Stocks to Buy for July 29th - Yahoo Finance
New Strong Buy Stocks for July 29th - Yahoo Finance
1.80%
大文字化:
|
ボリューム (24 時間):